Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Levofloxacin for Prevention of Gut Infection in De-novo AML
ChiCTR-IPR-17011239Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levofloxacin in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: event free survival. Started May 2017; status: recruiting.
02
Drugs
levofloxacin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IPR-17011239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011239.